

***What Is Claimed Is:***

Sub. A1  
B1  
1. A method of screening for therapeutics for infectious diseases,  
comprising:

5 (a) identifying host cell gene products selected from the group  
consisting of: host cell gene products which are upregulated during infection and  
host cell gene products which are expressed only during infection;

(b) screening said host cell gene products for immunogenicity;  
and

10 (c) determining which of said host cell gene products are  
immunogenic.

2. The method of claim 1, wherein said host cell gene products which  
are upregulated are expressed at a low level in uninfected cells of the same type.

3. The method of claim 1, wherein said host cell gene products which  
are upregulated are not expressed at all in uninfected cells of the same type.

15 4. The method of claim 1, wherein said infection is infection with  
human immunodeficiency virus (HIV).

5. The method of claim 1, wherein said screening for  
immunogenicity is screening for a cytotoxic T lymphocyte (CTL) response.

20 6. The method of claim 1, wherein said host cell gene products of (a)  
are identified using ordered microarrays of nucleic acids.

7. The method of claim 1, wherein said host cell gene products of (a)  
are identified using subtractive hybridization.

8. The method of claim 1, comprising:

- (a) identifying host cell gene products selected from the group consisting of: host cell gene products which are upregulated during infection and host cell gene products which are expressed only during infection;
- (b) identifying which of said host cell gene products of (a) are expressed during embryonic development;
- (c) screening the host cell gene products of (b) for immunogenicity; and
- (d) determining which of said host cell gene products of (b) are immunogenic.

9. The method of claim 8, comprising:

- (a) identifying host cell gene products selected from the group consisting of: host cell gene products which are upregulated during infection and host cell gene products which are expressed only during infection;
- (b) identifying which of said host cell gene products of (a) are expressed during embryonic development;
- (c) identifying which of said host cell gene products of (b) are not expressed in adult tissues;
- (d) screening said host cell gene products of (c) for immunogenicity; and
- (e) determining which of said host cell gene products of (c) are immunogenic.

10. The method of claim 8, wherein said host cell gene products of (a) are identified using ordered microarrays of nucleic acids.

11. The method of claim 8, wherein said host cell gene products of (a) are identified using subtractive hybridization.

12. The method of claim 8, wherein said host cell gene products of (b) are identified using ordered microarrays of nucleic acids.

13. The method of claim 8, wherein said host cell gene products of (b) are identified using subtractive hybridization.

14. The method of claim 9, wherein said host cell gene products of (a) are identified using ordered microarrays of nucleic acids.

15. The method of claim 9, wherein said host cell gene products of (a) are identified using subtractive hybridization.

16. The method of claim 9, wherein said host cell gene products of (b) are identified using ordered microarrays of nucleic acids.

17. The method of claim 9, wherein said host cell gene products of (b) are identified using subtractive hybridization.

18. The method of claim 9, wherein said host cell gene products of (c) are identified using ordered microarrays of nucleic acids.

19. The method of claim 9, wherein said host cell gene products of (c) are identified using subtractive hybridization.

20. The method of claim 8, wherein said infection is infection with human immunodeficiency virus (HIV).

21. The method of claim 8, wherein said screening for immunogenicity is screening for a cytotoxic T lymphocyte (CTL) response.

22. The method of claim 9, wherein said infection is infection with human immunodeficiency virus (HIV).

23. The method of claim 9, wherein said screening for immunogenicity is screening for a cytotoxic T lymphocyte (CTL) response.

096946-1001